Clinical trials: Active Acne
Acne Vulgaris
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
- Trial name
- NCT04797793
- Testing
- Adapalene Gel 0.1%, Differin® Gel (Adapalene 0.1%, Galderma)
- Where
- United States
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
EPIDUO™ (adapalene and benzoyl peroxide) Gel 0.1%/2.5%, marketed by GALDERMA LABORATORIES, L.P., is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01501799
- Testing
- adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO
- Where
- 25 sites in United States, Belize and 1 more
- Volunteers
- 885 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
Dose Range Study of CD5789 in Acne Vulgaris
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
- Trial name
- NCT01616654
- Testing
- CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream
- Where
- 24 sites in United States
- Volunteers
- 304 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%).
- Trial name
- NCT02411942
- Testing
- Adapalene Gel 0.3%, Differin®
- Volunteers
- 753 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Acne Treatment With Active Oplon's Patches
The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.
- Trial name
- NCT01180543
- Testing
- Oplon Active Patch
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Oplon-Pure Science Ltd.
Acne Vulgaris
Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne
This is a Randomized, Double-Blind, Controlled Study to evaluate the Safety and Efficacy of a clindamycin / benzoyl peroxide gel in Subjects with Acne Vulgaris
- Trial name
- NCT00776919
- Testing
- clindamycin / benzoyl peroxide gel, clindamycin gel, BPO gel
- Where
- 24 sites in United States, Belize and 1 more
- Volunteers
- 1,315 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels
The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).
- Trial name
- NCT01138514
- Testing
- Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo), Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
- Volunteers
- 1,555 people
- Sponsor
- Padagis LLC
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of…
- Trial name
- NCT06733402
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Platelet-Rich Plasma, Acne Vulgaris
Efficacy and Antimicrobial Activity of Platelet Rich Plasma (PRP) in Acne Vulgaris
Efficacy and Antimicrobial activity of Platelet Rich Plasma (PRP) in Acne Vulgaris : A randomized controlled trial
- Trial name
- NCT03859843
- Testing
- PRP, Chemical peeling (Salycilic acid), Chemical peeling (Jessener's solution)
- Volunteers
- 50 people
- Sponsor
- Assiut University
Hidradenitis Suppurativa
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis…
- Trial name
- NCT05322473
- Testing
- Sonelokimab (M1095), Adalimumab
- Where
- 57 sites in United States, Bulgaria and 5 more
- Volunteers
- 234 people
- Sponsor
- MoonLake Immunotherapeutics AG
Acne Vulgaris
Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid
The purpose of this study was to demonstrate the effect of short treatment with active OPLON patches on Acne.
- Trial name
- NCT01179633
- Testing
- OPLON active patch
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Oplon-Pure Science Ltd.
Acne Vulgaris
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
Marketed by Galderma Laboratories, L.P., Differin® (adapalene 0.3% topical gel) is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01095640
- Testing
- adapalene 0.3% topical gel
- Where
- India
- Volunteers
- 1,159 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris
Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.
- Trial name
- NCT02865005
- Testing
- Dapsone 5.0% Gel (SEEGPharm), Dapsone 5.0% Gel (Allergan)
- Where
- 36 sites in United States, Belize
- Volunteers
- 2,361 people
- Sponsor
- Seegpharm S.A.
Wrinkle, Fine Lines
Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions
The goal of the Potenza device used in this study is to collect clinical data for dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.
- Conditions
- Wrinkle, Fine Lines, Crepey Skin, Acne Scars
- Trial name
- NCT05987319
- Testing
- RadioFrequency Microneedling Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cynosure, Inc.
Acne Vulgaris
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel…
- Trial name
- NCT01769235
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, Acanya® Gel, 1.2%/2.5%, Vehicle of test product
- Volunteers
- 1,215 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12…
- Trial name
- NCT02073448
- Testing
- GK530G, CD0271, CD1579
- Where
- 13 sites in Japan
- Volunteers
- 417 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
The objectives of this study are to evaluate the therapeutic equivalence and safety.
- Trial name
- NCT02578043
- Testing
- Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%, Onexton™ Gel
- Volunteers
- 844 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne
A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris
The objective of this study was to evaluate the efficacy and safety of Perrigo's test formulation of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% compared to the already marketed formulation, Acanya gel in…
- Trial name
- NCT01796665
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%, Acanya Gel
- Volunteers
- 1,180 people
- Sponsor
- Padagis LLC
Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily.
- Trial name
- NCT03341910
- Testing
- DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Acne Vulgaris
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
Bioequivalence study comparing Tretinoin Cream, 0.05% to RETIN-A®.
- Trial name
- NCT03433378
- Testing
- Tretinoin cream, 0.05%, RETIN-A® (tretinoin) cream, 0.05%, Vehicle of the test product
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.